ArticleFrontiers in veterinary science2025
Cyclooxygenase-2 and von Willebrand factor-an immunohistochemical study of the equine foot with and without laminitis, post-mortem perfused with paraffin oil.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Equine laminitis is a complex and potentially fatal disease characterized by severe vascular and inflammatory alterations within the equine foot. This study aimed to develop immunohistochemistry (IHC) protocols for the detection of cyclooxygenase-2 (COX-2) and von Willebrand factor (vWF) in equine feet with and without laminitis, post-mortem perfused with paraffin oil. Materials and methods: A total of 12 equine forelimbs from 8 horses were utilized in this study, divided into two study cohorts: one with laminitis and the other as a non-laminitis control. To develop the IHC protocols thoroughly, the tissue samples were categorized into three groups: fresh, frozen-thawed, and frozen-thawed-perfused. IHC protocols for COX-2, a marker for inflammation, and vWF, a marker for vascular endothelial cells, were developed, respectively, optimized for use across these tissue groups. Samples from both study cohorts were processed and morphologically analyzed to assess tissue preservation and efficacy of immunostaining techniques. Results: Once the optimal paraffin embedding as well as combination of blocking reagents, blocking duration and antibodies had been empirically determined, COX-2 and vWF immunostaining were successful in all tissue groups. Reducing the embedding time in paraffin from 24 h to 2 h and positioning the samples at a 45° angle within the embedding cassette optimized the cutting results for microtome sectioning. Immunostaining specificity was good and results of COX-2 and vWF in both study cohorts were comparable and reliable between all three tissue groups. COX-2 was considerably elevated in the laminits cohort, predominantly in basal and parabasal cells, fibroblasts, and endothelial cells. vWF immunostaining effectively highlighted the vascular endothelial cells, revealing vascular compression and dilation, especially in the laminitis cohort. Conclusion/discussion: This study provides evidence that COX-2 and vWF can be reliably detected in equine lamellar hoof tissues, after undergoing freezing, thawing, and perfusion treatments. The established IHC protocols represent valuable diagnostic tools for studying the inflammatory and vascular changes associated with the equine foot. These methods can be applied to post-mortem cadaver models that have been frozen and perfused with paraffin oil, thus reducing the number of live animals required for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.